×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACRS – aclaris therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACRS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/29
09:00 am
acrs
Aclaris Therapeutics (ACRS) had its "outperform" rating reaffirmed by Wedbush.
Medium
Report
Aclaris Therapeutics (ACRS) had its "outperform" rating reaffirmed by Wedbush.
4/28
02:05 pm
acrs
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript [Seeking Alpha]
Low
Report
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript [Seeking Alpha]
4/28
10:22 am
acrs
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus [Yahoo! Finance]
4/28
07:32 am
acrs
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication f
Low
Report
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication f
4/28
06:30 am
acrs
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication f
High
Report
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication f
4/27
04:45 pm
acrs
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
Medium
Report
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
4/16
08:50 am
acrs
Aclaris Therapeutics (ACRS) was given a new $10.00 price target by UBS Group AG.
Low
Report
Aclaris Therapeutics (ACRS) was given a new $10.00 price target by UBS Group AG.
4/16
07:15 am
acrs
Aclaris Therapeutics (ACRS) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Low
Report
Aclaris Therapeutics (ACRS) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2026
06:58 am
ACRS
aclaris therapeutics, inc.
MISS
Report
-7.8%
aclaris therapeutics, inc.
11/6/2025
06:59 am
ACRS
aclaris therapeutics, inc.
BEAT
Report
0.4%
aclaris therapeutics, inc.
8/7/2025
06:59 am
ACRS
aclaris therapeutics, inc.
IN-LINE
Report
1.3%
aclaris therapeutics, inc.
5/8/2025
06:50 am
ACRS
aclaris therapeutics, inc.
BEAT
Report
7.4%
aclaris therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/28
06:45 am
acrs
Form 8-K Aclaris Therapeutics, For: Apr 28
High
Report
Form 8-K Aclaris Therapeutics, For: Apr 28
4/27
07:27 pm
acrs
Form 4 Aclaris Therapeutics, For: Apr 27 Filed by: Leonard Braden Michael
Medium
Report
Form 4 Aclaris Therapeutics, For: Apr 27 Filed by: Leonard Braden Michael
4/27
07:26 pm
acrs
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
Medium
Report
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.
4/23
07:48 am
acrs
Form ARS Aclaris Therapeutics, For: Dec 31
Medium
Report
Form ARS Aclaris Therapeutics, For: Dec 31
4/23
07:47 am
acrs
Form DEFA14A Aclaris Therapeutics,
Medium
Report
Form DEFA14A Aclaris Therapeutics,
4/23
07:45 am
acrs
Form DEF 14A Aclaris Therapeutics, For: Jun 04
Medium
Report
Form DEF 14A Aclaris Therapeutics, For: Jun 04
4/7
06:00 pm
acrs
Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Medium
Report
Form SCHEDULE 13G Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
3/26
03:06 pm
acrs
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/16
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
63.6%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
11/7 Form 8-K Aclaris Therapeutics, For: Nov 07 39.3%
10/10 Aclaris Therapeutics Announces Divestiture of RHOFADE® 19.3%
1/9 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor 17.2%
10/15 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.1%
7/9 Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1% 9.1%
12/19 Form SC 13D/A Aclaris Therapeutics, Filed by: Arkin Moshe 8.8%
9/5 Aclaris Therapeutics Inc (NASDAQ: ACRS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.6%
10/31 Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 8.0%
2/10 Form SC 13G/A Aclaris Therapeutics, Filed by: Man Group plc 7.9%
TOP News Decliners
6/26
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
-52.1%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
7/30 Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS) -39.0%
2/25 Form 10-K Aclaris Therapeutics, For: Dec 31 -22.2%
8/8 Form 10-Q Aclaris Therapeutics, For: Jun 30 -13.5%
9/25 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm -11.7%
11/21 Form 8-K Aclaris Therapeutics, For: Nov 21 -11.2%
3/31 Form 8-K Aclaris Therapeutics, For: Mar 30 -11.1%
9/17 Aclaris Therapeutics to Hold R&D Day -10.9%
3/6 Form SC 13G Aclaris Therapeutics, Filed by: Samsara BioCapital, L.P. -10.8%
5/8 Form 10-Q Aclaris Therapeutics, For: Mar 31 -10.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: